Third-space endoscopy moves from experimental access to routine GI therapy
Third-space endoscopy has shifted the therapeutic center of gravity in gastroenterology by turning the submucosal layer into a working space rather than a barrier. The method depends on a simple but powerful design: create a submucosal tunnel, preserve the mucosal surface, and separate the access route from the intervention site. In practice, this mucosal flap acts as a safety valve, limiting contamination while giving endoscopists a controlled route to deeper targets inside the gastrointestinal wall. The approach now reaches beyond its original conceptual roots and into several disorders that once belonged almost exclusively to surgery.
Its evolution began with submucosal endoscopy with mucosal flap, then moved through the first porcine per-oral endoscopic myotomy and later into human application nearly two decades ago. From there, the platform expanded rather than stalled. Achalasia became the defining proof of concept because the technique could release a dysfunctional sphincter without an external incision, and because myotomy could be delivered precisely along a tunnel that protected the mucosa above it. Once that anatomy was mastered, the same logic could be repurposed for other targets with different physiology but similar technical needs.
A single procedural principle now supports a growing family of interventions.
A shared tunnel architecture underlies the major procedure families
Across the current third-space endoscopy toolkit, the common denominator is not the indication but the anatomy of access. The submucosal tunnel gives operators a protected corridor for cutting, dissecting, or resecting while maintaining continuity of the luminal lining. In procedural terms, that preserves the internal seal until the work is finished, which reduces the exposure of deeper layers to luminal contents. Clinically, the result is a minimally invasive route that can substitute for operations once considered necessary for motility disorders, diverticula, and selected subepithelial lesions.
Per-oral endoscopic myotomy remains the best-established of these procedures. Its role in achalasia is now firmly embedded in clinical practice, and the review describes it as a therapy that has transformed management of the disorder rather than merely supplementing older approaches. That transformation matters because achalasia is a mechanical problem of outflow obstruction, and myotomy addresses the obstructive physiology directly. By disrupting the hypercontractile or nonrelaxing muscle segment, the procedure changes the pressure gradient at the esophagogastric junction and restores transit in a way that pharmacologic therapy rarely achieves.
Submucosal tunneling endoscopic resection has followed a related path for sub-epithelial tumors. The appeal here is anatomical precision: the lesion can be approached from within the tunnel and removed while the overlying mucosa remains intact or can be closed after resection. For tumors arising beneath the epithelium, that strategy reduces the need for a more invasive surgical exposure. In centers with appropriate expertise, the technique now occupies a defined place in management algorithms rather than an exploratory niche.
Expansion beyond achalasia has created new therapeutic pressure points
The field’s real momentum comes from its extension into disorders with less settled pathways. Refractory gastroparesis is a good example. Per-oral endoscopic myotomy in this setting aims to relieve pyloric dysfunction by reducing resistance to gastric emptying, but the physiology is more heterogeneous than in achalasia. Delayed gastric emptying can reflect neuromuscular impairment, impaired accommodation, medication effects, or broader motility disturbance, so the procedure may benefit some patients more than others. The review describes encouraging safety and efficacy signals, yet patient selection, duration of benefit, and comparative performance against other interventions remain unresolved.
Zenker’s per-oral endoscopic myotomy illustrates a different anatomic logic. Here the objective is to divide the septum that creates functional obstruction and regurgitation, using endoscopic access rather than open or rigid surgical exposure. The technique is attractive because the defect is localized and the symptom burden can be substantial, but long-term durability still needs clarification. Clinical adoption will depend on whether symptom control persists and whether recurrence rates remain acceptable as more patients are treated across broader practice settings.
Epiphrenic diverticula represent yet another extension of the same submucosal philosophy. The disorder is rare, and management has historically required surgery with myotomy to address the underlying motility abnormality. Endoscopic myotomy offers a less invasive path by targeting the pressure component that drives diverticular formation and symptoms. Even so, the evidence base is thinner than for achalasia, so the procedure remains more dependent on expertise and careful case selection.
Safety, durability, and selection remain the practical limits
The review positions third-space endoscopy as a minimally invasive alternative for several diseases traditionally managed surgically, but its spread has not erased clinical uncertainty. Some procedures now have mature roles; others still live in the space between feasibility and standardization. The central question is not whether tunneling techniques work at all. They do. The issue is which patients benefit most, how long the benefit lasts, and how these outcomes compare with established surgical or endoscopic options.
A durable therapeutic effect depends on more than technical success. In achalasia, the physiologic target is clear and the result is often durable enough to anchor routine care. In gastroparesis, symptom pathways are broader and more variable, so outcome heterogeneity is likely. In tumor resection, the key concern shifts toward complete removal and procedural safety. Each indication places a different stress on the same access strategy, which is why the field continues to expand while still demanding disciplined interpretation of results.
The review also makes clear that the adaptability of third-space endoscopy is a strength only when the procedural core remains standardized. The tunnel, the mucosal flap, and the separation of access from therapy are not minor technical details; they are the reason the method can move across disease categories without losing its internal logic. As indications widen, comparative studies and longer follow-up will determine where endoscopic tunneling becomes a durable standard and where it stays a high-skill alternative reserved for specialized centers.
For now, the field is defined by a split reality. Per-oral endoscopic myotomy and tunneling resection for subepithelial tumors have established themselves in clinical algorithms, while gastroparesis, Zenker’s myotomy, and epiphrenic diverticulum treatment still need clearer boundaries around selection, durability, and comparative effectiveness. The technical platform is already in place. The next stage will depend on proving which disease states can be treated with confidence, and which should still be approached with caution.